The identification of biomarkers represents the future of medicine – by measuring these molecules, we are able to detect disease earlier, discover the detailed state of a patient’s health and find the drugs that will be most effective to treat a patient’s individual disease.
Yale research into biomarkers has led to discoveries of gene profiles that can predict outcomes and lead to better treatment for lung disease; that can help identify patients at risk for kidney injury following heart surgery; and that can provide key information on how a threatening bacteria that targets neonates develops. A team led by Yale researchers in 2009 was the first to measure cancer biomarkers in whole blood—opening the door for easier, and more precise, early cancer detection.
Yale researchers are also finding new ways to measure biomarkers – including the design of a fiberoptic probe that can detect the accumulation of carotenoids in the skin. The startup IsoPlexis, formed through the Technology Commercialization Program (link to TCP) jointly run by the Office of Cooperative Research and the Yale Entrepreneurial Institute, brought together technology for discovering novel biomarkers with a single cell assay from Yale labs with support from a Yale SOM and Yale College student.